After yet another FDA delay regarding Vascepa's NCE status, Amarin (AMRN -1.32%) investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline (GSK 0.08%). In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.